Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
Core royalty platform on track; receiving GSK royalties of $61.9 million
核心特許權使用費平台步入正軌；獲得6190萬美元的葛蘭素史克特許權使用費
Achieved net product revenues of $19.1 million, representing 66% year-over-year growth driven by launch of XACDURO and growth of key core product GIAPREZA
實現淨產品收入1,910萬美元，同比增長66％，這得益於XACDURO的推出和關鍵核心產品GIAPREZA的增長
Strong pipeline progress: positive Phase 3 zoliflodacin clinical trial results in uncomplicated gonorrhea highlighted at ESCMID Global 2024; on track to submit NDA in early 2025
強勁的研發進展：在ESCMID Global 2024上重點介紹了佐利氟達辛3期臨床試驗的陽性結果；有望在2025年初提交保密協議
Derek Small appointed to the Company's Board of Directors
德里克·斯莫爾被任命爲公司董事會成員
BURLINGAME, Calif.--(BUSINESS WIRE)--May 8, 2024-- Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the first quarter ended March 31, 2024, and highlighted select corporate achievements.
加利福尼亞州伯林格姆--（美國商業資訊）--2024年5月8日--Innoviva, Inc.（納斯達克股票代碼：INVA）（“Innoviva” 或 “公司”）是一家多元化控股公司，擁有核心特許權使用費組合、名爲Innoviva Specialty Therapeutics（“IST”）的領先重症監護和傳染病平台以及醫療資產戰略投資組合，今天公佈了截至2024年3月31日的第一季度財務業績，以及重點介紹了部分企業成就。
"Our first quarter financial results continue to demonstrate the successful transformation for Innoviva. We had a strong performance driven by resilient cash flows from our core GSK royalties portfolio and robust revenue growth across our commercial products marketed by IST, a leader in critical care medicine and infectious disease," said Pavel Raifeld, Chief Executive Officer of Innoviva. "We also remain laser focused on utilizing our strong financials to drive shareholder value by continuing to exercise cost discipline, investing prudently in our strategic healthcare assets, and completing our share buyback plan."
“我們的第一季度財務業績繼續表明Innoviva的成功轉型。Innoviva首席執行官帕維爾·雷菲爾德說，我們的強勁表現得益於葛蘭素史克核心特許權使用費組合的彈性現金流以及重症監護醫學和傳染病領域的領導者IST銷售的商業產品的強勁收入增長。“我們還繼續專注於通過繼續實行成本紀律、謹慎投資我們的戰略醫療資產以及完成股票回購計劃，利用我們強勁的財務狀況來提高股東價值。”
Matt Ronsheim, Ph.D., President of IST, noted: "Our IST platform is a powerful engine for growth anchored by a robust portfolio of differentiated life saving therapies. We are pleased with our first quarter performance, led by the strong launch of our novel therapeutic XACDURO. Our core products GIAPREZA and XERAVA continue to grow, propelled by increasing awareness of our strong data underscoring the value of our products. We are also excited about our lead pipeline product, zoliflodacin, a potential first in class well tolerated oral drug for uncomplicated gonorrhea, whose Phase 3 data was highlighted in an oral presentation by our non-profit partner GARDP at ESCMID Global 2024, the largest global infectious disease congress. We remain on track to submit our New Drug Application for zoliflodacin in early 2025."
IST總裁馬特·龍斯海姆博士指出：“我們的IST平台是強大的增長引擎，其基礎是強大的差異化救生療法組合。我們對第一季度的表現感到滿意，這得益於我們新療法XACDURO的強勁推出。我們的核心產品GIAPREZA和XERAVA持續增長，這得益於人們對強調我們產品價值的強大數據的認識不斷提高。我們還對我們的主要研發產品唑利氟達辛感到興奮，這是一款潛在的治療無併發症淋病的同類首款耐受性良好的口服藥物，我們的非營利合作伙伴GARDP在最大的全球傳染病大會ESCMID Global 2024上做了口頭陳述，重點介紹了其三期數據。我們仍有望在2025年初提交佐利氟達辛的新藥申請。”
Financial Highlights
財務要聞
- Royalty revenue: First quarter 2024 gross royalty revenue from Glaxo Group Limited ("GSK") was $61.9 million, compared to $60.3 million for the first quarter of 2023.
- Net Product Sales: First quarter 2024 net product sales and license revenue were $19.1 million, which included $12.1 million from GIAPREZA, $4.8 million from XERAVA, and $2.2 million from XACDURO, a 66% increase compared to $11.5 million for the first quarter of 2023.
- Equity and long-term investments: First quarter 2024 net change in fair values of equity and long-term investments of $22.0 million was primarily attributable to Armata Pharmaceuticals ("Armata") share price appreciation.
- Net income: First quarter 2024 net income was $36.5 million, or $0.58 basic per share, compared to a net income of $34.9 million, or $0.51 basic per share, for the first quarter of 2023.
- Share repurchases: During the first quarter 2024, Innoviva repurchased 0.6 million shares of its outstanding common stock for $9.7 million. Subsequent to March 31, 2024, and through April 25, 2024, we completed the program by repurchasing 0.4 million shares for a total amount of approximately $5.3 million.
- Cash and cash equivalents: Totaled $178.4 million. Royalty and net product sales receivables totaled $76.0 million as of March 31, 2024.
- 特許權使用費收入： 葛蘭素集團有限公司（“葛蘭素史克”）2024年第一季度的特許權使用費總收入爲6,190萬美元，而2023年第一季度爲6,030萬美元。
- 產品淨銷售額： 2024年第一季度的淨產品銷售額和許可收入爲1,910萬美元，其中包括來自GIAPREZA的1,210萬美元，來自XERAVA的480萬美元和來自XACDURO的220萬美元，與2023年第一季度的1150萬美元相比增長了66％。
- 股票和長期投資：2024年第一季度股票和長期投資公允價值淨變動2,200萬美元，這主要歸因於Armata Pharmicals（“Armata”）股價上漲。
- 淨收入：2024年第一季度的淨收入爲3,650萬美元，合每股基本收益0.58美元，而2023年第一季度的淨收入爲3,490萬美元，合每股基本收益0.51美元。
- 股票回購： 在2024年第一季度，Innoviva以970萬美元的價格回購了60萬股已發行普通股。在2024年3月31日之後以及截至2024年4月25日，我們完成了該計劃，回購了40萬股股票，總金額約爲530萬美元。
- 現金和現金等價物：總額爲1.784億美元。截至2024年3月31日，特許權使用費和產品淨銷售應收賬款共計7,600萬美元。
Key Business and R&D Highlights
主要業務和研發亮點
- XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use: targeted antibacterial for patients with HABP/VABP caused by Acinetobacter
- Following the launch in September 2023, commercial efforts continue to deliver strong performance with growing number of health systems integrating XACDUROinto their protocols.
- Zoliflodacin: a potential first-in-class, single dose, oral antibiotic in development for the treatment of patients with uncomplicated gonorrhea
- Positive Phase 3 zoliflodacin clinical trial results highlighted in an oral presentation given by the Company's non-profit partner, The Global Antibiotic Research & Development Partnership (GARDP), at the European Society of Clinical Microbiology and Infectious Disease Global Congress (ESCMID Global 2024).
- The data showed that in the micro-intent-to-treat population (n=744), zoliflodacin achieved a microbiological cure rate of 90.9%, a 5.3% difference compared to ceftriaxone and azithromycin, the current global standard of care, which achieved a 96.2% cure rate (95% CI: 1.4%, 8.7%). Microbiological cure rates at extragenital sites were comparable between treatment arms (secondary endpoints). Zoliflodacin was generally well tolerated and emergent adverse events were comparable between treatment arms (46.2% vs 46.4%). No deaths or other serious adverse events were reported.
- The Company expects a New Drug Application to be submitted to the U.S. FDA in early 2025.
- XACDURO （注射用舒巴坦；注射用度洛巴坦），共同包裝用於靜脈注射：針對由以下原因引起的HABP/VABP患者的靶向抗菌 不動桿菌
- 繼2023年9月推出之後，隨着越來越多的衛生系統集成了XACDURO，商業努力繼續提供強勁的業績加入他們的協議。
- 佐利氟達星: 一種潛在的同類首創單劑量口服抗生素，用於治療無併發症的淋病患者
- 公司的非營利合作伙伴全球抗生素研究與開發夥伴關係（GARDP）在歐洲臨床微生物學和傳染病學會全球大會（ESCMID Global 2024）上的口頭陳述中重點介紹了佐利氟達辛的3期臨床試驗陽性結果。
- 數據顯示，在微量意圖治療人群（n=744）中，唑立達辛的微生物治癒率爲90.9％，與當前全球護理標準頭孢曲松和阿奇黴素相比差5.3％，後者的治癒率爲96.2％（95％置信區間：1.4％，8.7％）。不同治療組之間的生殖器外部位的微生物治癒率相當（次要終點）。佐利氟達辛的耐受性總體良好，治療組之間出現的不良事件相似（46.2% 對 46.4%）。未報告死亡或其他嚴重不良事件。
- 該公司預計將在2025年初向美國食品藥品管理局提交新藥申請。
Strategic Healthcare Assets
戰略醫療資產
- Our portfolio of strategic assets under the Company's various subsidiaries was valued at $628.4 million as of March 31, 2024, compared to $561.0 million as of December 31, 2023. In the first quarter 2024, Innoviva invested an additional $35.0 million in one of our assets, Armata, to help advance its lead therapeutic phage candidates. In addition, Innoviva invested an additional $5.8 million, with accrued interest, in Gate Neurosciences to support its strategy of developing next generation targeted CNS therapies, and an additional $2.7 million into ImaginAb Inc. to support its radiopharmaceutical platform.
- 截至2024年3月31日，我們在公司各子公司下的戰略資產組合價值爲6.284億美元，而截至2023年12月31日爲5.61億美元。2024年第一季度，Innoviva向我們的資產之一Armata額外投資了3500萬美元，以幫助推進其主要的候選治療性噬菌體。此外，Innoviva向Gate Neurosciences額外投資了580萬美元（含應計利息），以支持其開發下一代靶向中樞神經系統療法的戰略，並向Imaginab Inc.額外投資270萬美元以支持其放射性藥物平台。
Corporate Updates
企業最新消息
- In April 2024, Derek Small, an accomplished biopharmaceutical entrepreneur and executive, joined the Company's Board of Directors.
- Management will participate in the upcoming Bank of America Securities Health Care Conference, taking place on May 15, 2024, in Las Vegas. A live webcast of the Company's corporate presentation is scheduled for 9:20 a.m. PT and can be accessed here. An archived replay will be available following the event.
- 2024 年 4 月，成就卓著的生物製藥企業家兼高管德里克·斯莫爾加入公司董事會。
- 管理層將參加即將於2024年5月15日在拉斯維加斯舉行的美國銀行證券醫療保健會議。公司公司演講的網絡直播定於太平洋時間上午 9:20 舉行，可以觀看 這裏。活動結束後將提供存檔重播。
About Innoviva
關於 Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
Innoviva是一家多元化的控股公司，擁有核心特許權使用費組合、名爲Innoviva Specialty Therapeutics（“IST”）的領先重症監護和傳染病平台，以及對醫療資產的戰略投資組合。Innoviva的特許權使用費投資組合包括與葛蘭素史克集團有限公司（“葛蘭素史克”）合作的呼吸資產。Innoviva有權從葛蘭素史克獲得銷售RELVAR/BREO ELLIPTA和ANORO ELLIPTA的特許權使用費。Innoviva的其他創新醫療資產包括因收購Entasis Therapeutics而產生的傳染病和重症監護資產，包括XACDURO（注射用舒巴坦；注射用度洛巴坦），經批准用於治療成人醫院獲得性細菌性肺炎和由易感菌株引起的呼吸機相關細菌性肺炎 baumannii-calcoaceticus 不動桿菌 複合物和目前正在開發的用於治療無併發症淋病的在研佐利氟達辛，拉霍亞製藥公司，包括GIAPREZA（血管緊張素II），已獲准增加感染性或其他分佈性休克成人的血壓，XERAVA（依拉環素）用於治療成人複雜腹內感染。
ANORO, RELVAR and BREO are trademarks of the GSK group of companies.
ANORO、RELVAR和BREO是葛蘭素史克集團公司的商標。
Forward Looking Statements
前瞻性陳述
This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, and future events. Innoviva intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. The words "anticipate", "expect", "goal", "intend", "objective", "opportunity", "plan", "potential", "target" and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements involve substantial risks, uncertainties, and assumptions. These statements are based on the current estimates and assumptions of the management of Innoviva as of the date of this press release and are subject to known and unknown risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Innoviva to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to: expected cost savings; lower than expected future royalty revenue from respiratory products partnered with GSK; the commercialization of RELVAR/BREO ELLIPTA, ANORO ELLIPTA, GIAPREZA, XERAVA and XACDURO in the jurisdictions in which these products have been approved; the strategies, plans and objectives of Innoviva (including Innoviva's growth strategy and corporate development initiatives); the timing, manner, and amount of potential capital returns to shareholders; the status and timing of clinical studies, data analysis and communication of results; the potential benefits and mechanisms of action of product candidates; expectations for product candidates through development and commercialization; the timing of regulatory approval of product candidates; and projections of revenue, expenses and other financial items; the impact of the novel coronavirus ("COVID-19"); the timing, manner and amount of capital deployment, including potential capital returns to stockholders; and risks related to the Company's growth strategy. Other risks affecting Innoviva are described under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" contained in Innoviva's Annual Report on Form 10-K for the year ended December 31, 2023 and Quarterly Reports on Form 10-Q, which are on file with the Securities and Exchange Commission ("SEC") and available on the SEC's website at www.sec.gov. Past performance is not necessarily indicative of future results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. The information in this press release is provided only as of the date hereof, and Innoviva assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.
本新聞稿包含某些 “前瞻性” 陳述，該術語在1995年《私人證券訴訟改革法》中定義，除其他外，涉及與目標、計劃、目標和未來事件有關的陳述。Innoviva希望將此類前瞻性陳述納入1934年《證券交易法》第21E條和1995年《私人證券訴訟改革法》中有關前瞻性陳述的安全港條款。“預期”、“期望”、“目標”、“打算”、“目標”、“機會”、“計劃”、“潛力”、“目標” 等詞語以及類似的表述旨在識別此類前瞻性陳述。此類前瞻性陳述涉及重大風險、不確定性和假設。這些陳述基於截至本新聞稿發佈之日Innoviva管理層當前的估計和假設，並受已知和未知的風險、不確定性、情況變化、假設和其他因素的影響，這些因素可能導致Innoviva的實際業績與前瞻性陳述中反映的結果存在重大差異。可能導致實際業績與此類前瞻性陳述所示結果存在重大差異的重要因素包括：預期的成本節約；與葛蘭素史克合作的呼吸系統產品的未來特許權使用費收入低於預期；RELVAR/BREO ELLIPTA、ANORO ELLIPTA、GIAPREZA、XERAVA和XACDURO在這些產品獲得批准的司法管轄區的商業化；Innoviva（包括Innoviva的增長戰略和企業發展計劃）；向股東提供潛在資本回報的時機、方式和金額；臨床研究、數據分析和結果交流的狀況和時機；候選產品的潛在收益和行動機制；通過開發和商業化對候選產品的預期；監管部門批准候選產品的時間；以及收入、支出和其他財務項目的預測；新型冠狀病毒（“COVID-19”）的影響；資本部署的時機、方式和金額，包括潛在資本退貨致股東；以及與公司增長戰略相關的風險。影響Innoviva的其他風險在 “風險因素” 和 “管理層對財務狀況和經營業績的討論與分析” 標題下進行了描述，這些標題載於Innoviva截至2023年12月31日止年度的10-K表年度報告和10-Q表季度報告，這些報告已提交給美國證券交易委員會（“SEC”），可在美國證券交易委員會（“SEC”）的網站上查閱 www.sec.gov。過去的表現不一定代表未來的業績。無法保證任何前瞻性陳述，實際結果可能與此類陳述存在重大差異。鑑於這些不確定性，您不應過分依賴這些前瞻性陳述。本新聞稿中的信息僅截至本文發佈之日提供，除非法律要求，否則Innoviva沒有義務根據新信息、未來事件或其他原因更新其前瞻性陳述。
| INNOVIVA, INC. | ||||||||
| Condensed Consolidated Statements of Income and Comprehensive Income | ||||||||
| (in thousands, except per share data) | ||||||||
| (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue: | ||||||||
| Royalty revenue, net (1) | $ | 58,415 | $ | 56,858 | ||||
| Net product sales | 19,084 | 11,514 | ||||||
| License Revenue | - | 8,000 | ||||||
| Total revenue | 77,499 | 76,372 | ||||||
| Expenses: | ||||||||
| Cost of products sold (inclusive of amortization of inventory fair value adjustments) | 10,971 | 8,749 | ||||||
| Cost of license revenue | - | 1,600 | ||||||
| Selling, general and administrative | 30,405 | 19,735 | ||||||
| Research and development | 3,878 | 12,588 | ||||||
| Amortization of acquired intangible assets | 6,440 | 3,805 | ||||||
| Changes in fair values of equity method investments, net | (35,342) | (15,817) | ||||||
| Changes in fair values of equity and long-term investments, net | 13,335 | 2,164 | ||||||
| Interest and dividend income | (4,399) | (3,365) | ||||||
| Interest expense | 5,851 | 4,427 | ||||||
| Other expense, net | 1,236 | 1,346 | ||||||
| Total expenses | 32,375 | 35,232 | ||||||
| Income before income taxes | 45,124 | 41,140 | ||||||
| Income tax expense | 8,592 | 6,275 | ||||||
| Net income and comprehensive income | $ | 36,532 | $ | 34,865 | ||||
| Net income per share | ||||||||
| Basic | $ | 0.58 | $ | 0.51 | ||||
| Diluted | $ | 0.46 | $ | 0.42 | ||||
| Shares used to compute net income per share | ||||||||
| Basic | 63,185 | 67,786 | ||||||
| Diluted | 84,531 | 89,788 | ||||||
| INNOVIVA, INC. | ||||||||
| 簡明合併損益表和綜合收益表 | ||||||||
| （以千計，每股數據除外） | ||||||||
| （未經審計） | ||||||||
| 三個月已結束 | ||||||||
| 3月31日 | ||||||||
| 2024 | 2023 | |||||||
| 收入： | ||||||||
| 特許權使用費收入，淨額 (1) | $ | 58,415 | $ | 56,858 | ||||
| 產品淨銷售額 | 19,084 | 11,514 | ||||||
| 許可證收入 | - | 8000 | ||||||
| 總收入 | 77,499 | 76,372 | ||||||
| 費用： | ||||||||
| 產品銷售成本（包括庫存公允價值調整的攤銷） | 10,971 | 8,749 | ||||||
| 許可證收入成本 | - | 1,600 | ||||||
| 銷售、一般和管理 | 30,405 | 19,735 | ||||||
| 研究和開發 | 3,878 | 12,588 | ||||||
| 收購的無形資產的攤銷 | 6,440 | 3,805 | ||||||
| 權益法投資公允價值的變動，淨額 | (35,342) | (15,817) | ||||||
| 股票和長期投資公允價值的變化，淨額 | 13,335 | 2,164 | ||||||
| 利息和股息收入 | (4,399) | (3,365) | ||||||
| 利息支出 | 5,851 | 4,427 | ||||||
| 其他費用，淨額 | 1,236 | 1,346 | ||||||
| 支出總額 | 32,375 | 35,232 | ||||||
| 所得稅前收入 | 45,124 | 41,140 | ||||||
| 所得稅支出 | 8,592 | 6,275 | ||||||
| 淨收益和綜合收益 | $ | 36,532 | $ | 34,865 | ||||
| 每股淨收益 | ||||||||
| 基本 | $ | 0.58 | $ | 0.51 | ||||
| 稀釋 | $ | 0.46 | $ | 0.42 | ||||
| 用於計算每股淨收益的股票 | ||||||||
| 基本 | 63,185 | 67,786 | ||||||
| 稀釋 | 84,531 | 89,788 | ||||||
| (1) Total net revenue is comprised of the following (in thousands): | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2024 | 2023 | |||||||
| (unaudited) | ||||||||
| Royalties | $ | 61,871 | $ | 60,314 | ||||
| Amortization of capitalized fees | (3,456) | (3,456) | ||||||
| Royalty revenue, net | $ | 58,415 | $ | 56,858 | ||||
| (1) 淨收入總額包括以下內容（以千計）： | ||||||||
| 三個月已結束 | ||||||||
| 3月31日 | ||||||||
| 2024 | 2023 | |||||||
| （未經審計） | ||||||||
| 特許權使用費 | $ | 61,871 | $ | 60,314 | ||||
| 資本化費用的攤銷 | (3,456) | (3,456) | ||||||
| 特許權使用費收入，淨額 | $ | 58,415 | $ | 56,858 | ||||
| INNOVIVA, INC. | |||||
| Condensed Consolidated Balance Sheets | |||||
| (in thousands) | |||||
| (unaudited) | |||||
| March 31, | December 31, | ||||
| 2024 | 2023 | ||||
| Assets | |||||
| Cash and cash equivalents | $ | 178,357 | $ | 193,513 | |
| Royalty and product sale receivables | 76,010 | 84,075 | |||
| Inventory, net | 37,437 | 40,737 | |||
| Prepaid expense and other current assets | 19,538 | 25,894 | |||
| Property and equipment, net | 324 | 483 | |||
| Equity and long-term investments | 628,437 | 560,978 | |||
| Capitalized fees | 80,328 | 83,784 | |||
| Right-of-use assets | 2,269 | 2,536 | |||
| Goodwill | 17,905 | 17,905 | |||
| Intangible assets | 223,895 | 230,335 | |||
| Other assets | 3,112 | 3,267 | |||
| Total assets | $ | 1,267,612 | $ | 1,243,507 | |
| Liabilities and stockholders' equity | |||||
| Other current liabilities | $ | 28,059 | $ | 33,435 | |
| Accrued interest payable | 833 | 3,422 | |||
| Deferred revenues | 987 | 1,277 | |||
| Convertible senior notes, due 2025, net | 191,476 | 191,295 | |||
| Convertible senior notes, due 2028, net | 255,283 | 254,939 | |||
| Other long term liabilities | 71,686 | 71,870 | |||
| Deferred tax liabilities | 3,807 | 563 | |||
| Income tax payable - long term | 11,800 | 11,751 | |||
| Innoviva stockholders' equity | 703,681 | 674,955 | |||
| Total liabilities and stockholders' equity | $ | 1,267,612 | $ | 1,243,507 | |
| INNOVIVA, INC. | |||||
| 簡明合併資產負債表 | |||||
| （以千計） | |||||
| （未經審計） | |||||
| 3月31日 | 十二月三十一日 | ||||
| 2024 | 2023 | ||||
| 資產 | |||||
| 現金和現金等價物 | $ | 178,357 | $ | 193,513 | |
| 特許權使用費和產品銷售應收賬款 | 76,010 | 84,075 | |||
| 庫存，淨額 | 37,437 | 40,737 | |||
| 預付費用和其他流動資產 | 19,538 | 25,894 | |||
| 財產和設備，淨額 | 324 | 483 | |||
| 股票和長期投資 | 628,437 | 560,978 | |||
| 資本化費用 | 80,328 | 83,784 | |||
| 使用權資產 | 2,269 | 2,536 | |||
| 善意 | 17,905 | 17,905 | |||
| 無形資產 | 223,895 | 230,335 | |||
| 其他資產 | 3,112 | 3,267 | |||
| 總資產 | $ | 1,267,612 | $ | 1,243,507 | |
| 負債和股東權益 | |||||
| 其他流動負債 | $ | 28,059 | $ | 33,435 | |
| 應計應付利息 | 833 | 3,422 | |||
| 遞延收入 | 987 | 1,277 | |||
| 2025年到期的可轉換優先票據，淨額 | 191,476 | 191,295 | |||
| 2028年到期的可轉換優先票據，淨額 | 255,283 | 254,939 | |||
| 其他長期負債 | 71,686 | 71,870 | |||
| 遞延所得稅負債 | 3,807 | 563 | |||
| 應繳所得稅-長期 | 11,800 | 11,751 | |||
| Innoviva 股東權益 | 703,681 | 674,955 | |||
| 負債和股東權益總額 | $ | 1,267,612 | $ | 1,243,507 | |
| INNOVIVA, INC. | |||||||
| Cash Flows Summary | |||||||
| (in thousands) | |||||||
| (unaudited) | |||||||
| Three Months Ended March 31, | |||||||
| 2024 | 2023 | ||||||
| Net cash provided by operating activities | $ | 37,047 | $ | 25,684 | |||
| Net cash used in investing activities | (43,038) | (35,722) | |||||
| Net cash used in financing activities | (9,165) | (136,962) | |||||
| Net change | $ | (15,156) | $ | (147,000) | |||
| Cash and cash equivalents at beginning of period | 193,513 | 291,049 | |||||
| Cash and cash equivalents at end of period | $ | 178,357 | $ | 144,049 | |||
| INNOVIVA, INC. | |||||||
| 現金流摘要 | |||||||
| （以千計） | |||||||
| （未經審計） | |||||||
| 截至3月31日的三個月 | |||||||
| 2024 | 2023 | ||||||
| 經營活動提供的淨現金 | $ | 37,047 | $ | 25,684 | |||
| 用於投資活動的淨現金 | (43,038) | (35,722) | |||||
| 用於融資活動的淨現金 | (9,165) | (136,962) | |||||
| 淨變化 | $ | (15,156) | $ | (147,000) | |||
| 期初的現金和現金等價物 | 193,513 | 291,049 | |||||
| 期末的現金和現金等價物 | $ | 178,357 | $ | 144,049 | |||
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508594441/en/
Innoviva, Inc.
David Patti
Corporate Communications
(908) 421-5971
david.patti@inva.com
Innoviva, Inc.
大衛帕蒂
企業傳播
(908) 421-5971
david.patti@inva.com
Investors and Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
投資者和媒體：
Argot Par
(212) 600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
資料來源：Innoviva, Inc.
譯文內容由第三人軟體翻譯。